Christine Fox
Equibles does not estimate personal net worth.
Get an email with a short summary when Mereo BioPharma Group plc publishes a filing, an earnings call transcript or a press release.
Get MREO alertsAbout Christine Fox
Christine Fox is recorded as CFO at Mereo BioPharma Group plc (MREO). The newest filing on record that lists Christine Fox as CFO at Mereo BioPharma Group plc (MREO) is dated April 9, 2026. The proxy statement of Teva Pharmaceutical Industries Ltd reports total compensation of $5,895,161 for Christine Fox in fiscal 2025, including a base salary of $849,231. Disclosed compensation is on record for 4 fiscal years. Mereo BioPharma Group plc is classified in the Biotechnology industry within the Healthcare sector. Teva Pharmaceutical Industries Ltd is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Mereo BioPharma Group plc includes Dr. Denise Scots-Knight (CEO and Board Member), Michael S. Wyzga (Chairman), Charles Sermon (General Counsel) and 7 others.
Affiliation history
-
Current
Start not stated–present
Last confirmed April 9, 2026
-
Teva Pharmaceutical Industries Ltd (TEVA)
Proxy statement
CurrentStart not stated–present
Last confirmed March 31, 2026
Company network
Drug Manufacturers - Specialty & Generic · Healthcare
Leadership on record at Mereo BioPharma Group plc
- Dr. Denise Scots-Knight CEO, Board Member
- Michael S. Wyzga Chairman
- Charles Sermon General Counsel
- Dr. Anders Ekblom Board Member
- Dr. Annalisa Jenkins Board Member
- Dr. Daniel Shames Board Member
- Dr. Deepika R. Pakianathan Board Member
- Dr. Jeremy Bender Board Member
- Dr. Pierre Jacquet Board Member
- Justin Roberts Board Member
Leadership on record at Teva Pharmaceutical Industries Ltd
- Richard Francis CEO, Board Member
- Eli Kalif CFO
- Amir Weiss Chief Accounting Officer
- Andrew Weil Chief Accounting Officer
- Abbas Hussain Board Member
- Chen Lichtenstein Board Member
- Dr. Sol J. Barer Board Member
- Nechemia (Chemi) J. Peres Board Member
- Prof. Varda Shalev Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Teva Pharmaceutical Industries Ltd (TEVA) | Executive Vice President, US Commercial | $849,231 | $5,895,161 |
| 2024 | Teva Pharmaceutical Industries Ltd (TEVA) | Executive Vice President, US Commercial | $800,000 | $5,218,023 |
| 2023 | Mereo BioPharma Group plc (MREO) | Chief Financial Officer | $378,120 | $1,001,051 |
| 2022 | Mereo BioPharma Group plc (MREO) | Chief Financial Officer | $332,833 | $810,939 |
Recent activity
No call appearances or filed executive changes recorded yet.